Arcutis Biotherapeutics, Inc’s Zoryve Gets FDA Approval for Seborrheic Dermatitis
Zoryve (roflumilast) topical foam, 0.3% is the first approved treatment for seborrheic dermatitis with a new mechanism of action in more than two decades. The FDA has approved Arcutis Biotherapeutics, Inc’s Zoryve (roflumilast) topical foam, 0.3% to treat seborrheic dermatitis…
GSK’s Jemperli Plus Zejula Produces Significant Survival Improvement in Endometrial Cancer
Jemperli plus standard-of-care chemotherapy with carboplatin and paclitaxel, followed by Jemperli plus Zejula as maintenance therapy produced a statistically significant and clinically meaningful benefit in progression-free survival in patients with primary advanced or recurrent endometrial cancer. GSK’s Jemperli (dostarlimab) produced a…
Moderna’s Novel mRNA Vaccine Shows Significant Efficacy Against RSV
Pivotal trial findings show favorable clinical safety and efficacy data for mRNA-1345 in lowering the incidence of respiratory syncytial virus-associated lower respiratory tract disease. The results of a pivotal Phase III trial show favorable clinical safety and efficacy data for…
The Top 5 Q&As of 2023
Pharm Exec spent the year speaking with some of the most interesting professionals from the life sciences industry.
Top Marketing Stories of 2023
Pharma marketing teams had to deal with big changes in 2023. Q&A With UCB’s Camille Lee on New Psoriasis Medication Approval The UCB executive speaks on recent FDA approval of Bimzelx. Artificial Intelligence Changing the Landscape for Healthcare Social Media…
The Top 5 DE&I Stories in 2023
As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023. Equity for Women in Healthcare: 131 Years is Too Long to Wait Closing the gender gap in pharma—and how we get there together….
Our Top 5 Podcast Episodes of 2023
Published on: December 27, 2023 Our top five episodes of the year. The Explosive Arrival of Chat GPT and Generative AIFran Pollaro talks with Faruk Capan is the CEO, EVERSANA INTOUCH & Chief Innovation Officer, EVERSANA about the arrival of Chat…
Top 5 AI Stories of 2023
As this exciting technology exploded in 2023, Pharm Exec was there to cover it all. The Promise and Challenges of Generative AI in Healthcare Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of…
Top Social Media Trends of 2023
Five trends in pharmaceutical marketing from the past year. Doctors as influencers A recent Hootsuite social trends presentation focused on healthcare revealed that a significant majority of Gen Z use social media platforms like TikTok and LinkedIn to look up…
FDA Approves Expanded Indication for LEO Pharma’s Adbry for Pediatric Patients With Atopic Dermatitis
Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable. The FDA has approved…
The Cover Stories of 2023
Enabling Authenticity Natalie Bickford, chief people officer at Sanofi, reveals how she approaches the employee experience, which ultimately influences employee retention, and discusses the importance of a corporate DE&I strategy in those efforts. Built for the Moment Starting out with…
FDA Approves Filsuvez for Epidermolysis Bullosa
Filsuvez (birch triterpenes) is indicated to treat partial thickness wounds associated with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa. The FDA has approved Chiesi Global Rare Diseases’ topical gel Filsuvez (birch triterpenes) to treat partial thickness wounds associated with junctional…
FDA Accepts Biologics License Application for CSL Behring’s Garadacimab for Hereditary Angioedema
Garadacimab is a novel, first-in-class, recombinant monoclonal antibody for hereditary angioedema that targets activated Factor XII. The FDA has accepted a Biologics License Application (BLA) for CSL Behring’s garadacimab (CSL312), a once-monthly prophylactic therapy for hereditary angioedema (HAE). A Marketing…
Maximizing ROI with Lab Software Solutions
Published on: December 21, 2023 Explore the implementation of enterprise laboratory software and the start of a digital transformation in your lab with an industry expert who discusses maximizing returns on investment, upholding data integrity while managing cost containment, and adopting…
The Transformative Potential of AI and Machine Learning in Biomedical Research and Healthcare
In a recent article published by Oxford Academic, authors discussed a number of ways that artificial intelligence (AI) and machine learning (ML) could transform biomedical research and healthcare. This includes enhancing operational efficiency, reducing costs, improving diagnostics, identifying therapeutic targets,…
Maximizing ROI with Lab Software Solutions (December 2023)
Published on: December 21, 2023 Explore the implementation of enterprise laboratory software and the start of a digital transformation in your lab with an industry expert who discusses maximizing returns on investment, upholding data integrity while managing cost containment, and adopting…
79% of Respondents Admit to Neglecting Health Needs During the Holiday Season
American Heart Association survey suggests holiday stress has a major impact on health habits. A recent survey released by the American Heart Association revealed that 79% of respondents tend to neglect their health needs during the holidays, focusing instead on…
Q&A With Christoph Bug, Vice President of Global Medical at Veeva
Data will continue to grow in importance in 2024. Many of the biggest stories in 2023 were related to technological advancements in the life sciences industry. These advancements have increased the importance of having high-quality data. Christoph Bug, vice president…
FDA Grants Priority Review to Genentech’s sBLA for Xolair to Treat Food Allergies
If approved by the FDA, Xolair would be the first drug indicated to lower allergic reactions to multiple foods after an accidental exposure, including peanut, milk, and egg allergies. The FDA has granted Priority Review to Genentech’s supplemental Biologics License…
Merck’s 21-Valent Pneumococcal Conjugate Vaccine Granted FDA Priority Review
Merck’s Biologics License Application for V116, a novel 21-valent pneumococcal conjugate vaccine has been given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024. The FDA has granted priority review to Merck’s Biologics License Application (BLA) for…
Study Finds Association Between Neighborhood-Level Socioeconomic Status, Medication Nonadherence Among Heart Failure Patients
JAMA study aims to discover whether ignoring medical advice relates to financial status among patients with heart failure. Recently published research points to a need for greater outreach efforts to improve medication uptake among underserved patient populations. In a JAMA…
The Price of Prescriptions: Getting it Right
Drug companies face new hurdles in a rapidly changing marketplace. How do they finance new drug development amid the uncertainty? How much is a prescription medicine really worth? For patients suffering from cancer or other severe illnesses where the right…
The Life Sciences Industry in 2023 and a View for 2024
In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management with strategic investments will be vital. The breakneck pace of digital transformation spurred by COVID-19 continued to reshape the life…
FDA Approves Padcev/Keytruda Combo for Locally Advanced, Metastatic Urothelial Cancer
In clinical trials, Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) produced a statistically significant improvement in survival compared to platinum-based chemotherapy alone in patients with locally advanced or metastatic urothelial cancer. The FDA has approved Padcev (enfortumab vedotin-ejfv; Astellas Pharma and…